Who Pays My Doctor?

Healthcare provider profile · identity verified

Michael E Cobble

Allopathic & Osteopathic Physicians|Family Medicine · SANDY, UT · NPI 1992927834

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Michael E Cobble received $362,119.60 in general payments during 2025 across 552 reported records.

Amgen Inc. accounted for 38.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 14 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Vraylar.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$362,119.60

552 reported records · 8 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Amgen Inc. Unresolved — no canonical attribution shown $139,819.4238.6%2262025
ABBVIE INC. Unresolved — no canonical attribution shown $116,805.2732.3%1902025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Unresolved — no canonical attribution shown $57,136.0415.8%752025
Vanda Pharmaceuticals Inc. Unresolved — no canonical attribution shown $35,810.769.9%452025
Novo Nordisk Inc Unresolved — no canonical attribution shown $12,463.013.4%112025
Lilly USA, LLC Unresolved — no canonical attribution shown $49.130.0%32025
Alkermes, Inc. Unresolved — no canonical attribution shown $19.800.0%12025
Novartis Pharmaceuticals Corporation Unresolved — no canonical attribution shown $16.170.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$292,693.75143
Travel and Lodging$42,627.63224
Consulting Fee$18,214.385
Food and Beverage$8,583.84180

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
REPATHA
Normalized: repatha		 Biological Amgen Inc. $133,656.35 219 2025
Source payment records
VRAYLAR
Normalized: vraylar		 Drug ABBVIE INC. $114,459.19 182 2025
Source payment records
CAPLYTA
Normalized: caplyta		 Drug ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $57,136.04 75 2025
Source payment records
FANAPT
Normalized: fanapt		 Drug Vanda Pharmaceuticals Inc. $35,810.76 45 2025
Source payment records
Ozempic
Normalized: ozempic		 Drug Novo Nordisk Inc $12,443.69 10 2025
Source payment records
Rybelsus
Normalized: rybelsus		 Drug Novo Nordisk Inc $49.16 2 2025
Source payment records
MOUNJARO
Normalized: mounjaro		 Drug Lilly USA, LLC $31.87 2 2025
Source payment records
ZEPBOUND
Normalized: zepbound		 Drug Lilly USA, LLC $31.87 2 2025
Source payment records
ARISTADA
Normalized: aristada		 Drug Alkermes, Inc. $19.80 1 2025
Source payment records
LYBALVI
Normalized: lybalvi		 Drug Alkermes, Inc. $19.80 1 2025
Source payment records
Wegovy
Normalized: wegovy		 Drug Novo Nordisk Inc $19.32 1 2025
Source payment records
KISUNLA
Normalized: kisunla		 Drug Lilly USA, LLC $17.26 1 2025
Source payment records
LEQVIO
Normalized: leqvio		 Drug Novartis Pharmaceuticals Corporation $16.17 1 2025
Source payment records
OTEZLA
Normalized: otezla		 Drug Amgen Inc. $14.20 3 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
MOUNJARO
mounjaro		 2025 Mounjaro 2024 11
Beneficiary count suppressed		 exact normalized Medicare Part D
Ozempic
ozempic		 2025 Ozempic 2024 37
Beneficiary count suppressed		 exact normalized Medicare Part D
VRAYLAR
vraylar		 2025 Vraylar 2024 11
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
ABBVIE INC.
Exact reporting entity; no affiliate inference		 2025 VRAYLAR
open payments reported associated product		 CMS Open Payments — General Payments
377741 supporting records · 62704 recipient NPIs · example record 1201352550 		Vraylar · 2024
Exact normalized brand match · 1 Part D row		 11 suppressed by CMS
Lilly USA, LLC
Exact reporting entity; no affiliate inference		 2025 MOUNJARO
open payments reported associated product		 CMS Open Payments — General Payments
186719 supporting records · 66436 recipient NPIs · example record 1186464455 		Mounjaro · 2024
Exact normalized brand match · 1 Part D row		 11 suppressed by CMS
Novo Nordisk Inc
Exact reporting entity; no affiliate inference		 2025 Ozempic
open payments reported associated product		 CMS Open Payments — General Payments
261625 supporting records · 77793 recipient NPIs · example record 1188130076 		Ozempic · 2024
Exact normalized brand match · 1 Part D row		 37 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Rosuvastatin CalciumRosuvastatin Calcium11237
EzetimibeEzetimibe9733
RamiprilRamipril6819
Levothyroxine SodiumLevothyroxine Sodium6418
Atorvastatin CalciumAtorvastatin Calcium6318
Amlodipine BesylateAmlodipine Besylate5519
Metformin Hcl ErMetformin Hcl5117
Pantoprazole SodiumPantoprazole Sodium5014
Montelukast SodiumMontelukast Sodium4612
Metformin HclMetformin Hcl4012
OzempicSemaglutide37suppressed
AzithromycinAzithromycin3116
AllopurinolAllopurinol27suppressed
CarvedilolCarvedilol27suppressed
Duloxetine HclDuloxetine Hcl26suppressed
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen25suppressed
Zolpidem TartrateZolpidem Tartrate25suppressed
SpironolactoneSpironolactone23suppressed
AtenololAtenolol22suppressed
OmeprazoleOmeprazole22suppressed
Trazodone HclTrazodone Hcl21suppressed
FarxigaDapagliflozin Propanediol20suppressed
Tamsulosin HclTamsulosin Hcl20suppressed
MeloxicamMeloxicam19suppressed
LisinoprilLisinopril18suppressed
PrednisonePrednisone1811
EliquisApixaban17suppressed
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17suppressed
Raloxifene HclRaloxifene Hcl17suppressed
ColchicineColchicine16suppressed
GabapentinGabapentin16suppressed
VascepaIcosapent Ethyl16suppressed
ClonazepamClonazepam15suppressed
IndomethacinIndomethacin15suppressed
Liothyronine SodiumLiothyronine Sodium15suppressed
Pravastatin SodiumPravastatin Sodium15suppressed
Icosapent EthylIcosapent Ethyl13suppressed
AlprazolamAlprazolam12suppressed
Citalopram HbrCitalopram Hydrobromide12suppressed
Cyclobenzaprine HclCyclobenzaprine Hcl12suppressed
DiazepamDiazepam12suppressed
Esomeprazole MagnesiumEsomeprazole Magnesium12suppressed
Ibandronate SodiumIbandronate Sodium12suppressed
MirtazapineMirtazapine12suppressed
OlanzapineOlanzapine12suppressed
Oxycodone HclOxycodone Hcl12suppressed
Praluent PenAlirocumab12suppressed
CarisoprodolCarisoprodol11suppressed
Ciprofloxacin HclCiprofloxacin Hcl11suppressed
Fluticasone PropionateFluticasone Propionate11suppressed
Losartan PotassiumLosartan Potassium11suppressed
Methylphenidate HclMethylphenidate Hcl11suppressed
MounjaroTirzepatide11suppressed
VraylarCariprazine Hcl11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $362,119.60 · 552 records Amgen Inc. ARISTADA, CAPLYTA, FANAPT, KISUNLA, LEQVIO, LYBALVI, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, VRAYLAR, Wegovy, ZEPBOUND 3 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error